Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the target of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 1,317,968 shares, an increase of 7.5% from the January 31st total of 1,225,623 shares. Currently, 1.8% of the company’s stock are short sold. Based on an average daily volume of 244,365 shares, the days-to-cover ratio is presently 5.4 days.
Shares of Matinas BioPharma (NYSEAMERICAN MTNB) opened at $0.99 on Thursday. Matinas BioPharma has a 52-week low of $0.83 and a 52-week high of $3.99. The stock has a market cap of $95.74, a price-to-earnings ratio of -2.68 and a beta of 0.38.
A number of hedge funds and other institutional investors have recently bought and sold shares of MTNB. Virtu Financial LLC lifted its stake in Matinas BioPharma by 126.0% during the 4th quarter. Virtu Financial LLC now owns 106,146 shares of the company’s stock valued at $123,000 after acquiring an additional 59,188 shares in the last quarter. BlackRock Inc. lifted its stake in Matinas BioPharma by 3.4% during the 4th quarter. BlackRock Inc. now owns 2,530,508 shares of the company’s stock valued at $2,935,000 after acquiring an additional 84,226 shares in the last quarter. Deutsche Bank AG lifted its stake in Matinas BioPharma by 184.8% during the 4th quarter. Deutsche Bank AG now owns 148,042 shares of the company’s stock valued at $171,000 after acquiring an additional 96,054 shares in the last quarter. American Century Companies Inc. bought a new position in Matinas BioPharma during the 4th quarter valued at $155,000. Finally, Yellowstone Partners LLC bought a new position in Matinas BioPharma during the 3rd quarter valued at $190,000.
ILLEGAL ACTIVITY NOTICE: “Short Interest in Matinas BioPharma Holdings Inc (MTNB) Expands By 7.5%” was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3229446/short-interest-in-matinas-biopharma-holdings-inc-mtnb-expands-by-7-5.html.
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.